Abbott Laboratories (ABT) Guidance & Earnings Results
On 2026-10-21 Abbott Laboratories reaffirmed guidance: "FY2026 adjusted diluted EPS guidance $5.50-$5.55 (tightened from prior range); FY2026 comparable sales growth…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ABTAbbott LaboratoriesFollow ABT — free
—
Price chart with a free account
- Market cap
- 179.4B
- P/E TTM
- 33.5
- Dividend yield
- 2.4%
- 52-week
- —
- Next earnings
- 20 Jan, in 87 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 21 Oct 26 | Reaffirmed | FY2026 adjusted diluted EPS guidance $5.50-$5.55 (tightened from prior range); FY2026 comparable sales growth ~6.0% · full year |
| 16 Jul 26 | Raised | FY2026 adjusted diluted EPS raised to $5.45-$5.60 from $5.38-$5.58; FY2026 comparable sales growth reaffirmed at 6.5%-7.5% · full year |
| 16 Apr 26 | Raised | Full-year 2026 comparable sales growth guidance raised to 6.5%-7.5% and adjusted diluted EPS guidance of $5.38-$5.58 · full year |
| 22 Jan 26 | Raised | FY2026 organic sales growth 6.5%-7.5%, adjusted EPS $5.55-$5.80 (10% growth at midpoint) · full year |
| 15 Oct 25 | Raised | Narrowed adjusted EPS range to $5.12-$5.18 from prior range; reaffirmed organic sales growth guidance · full year |
Abbott Laboratories — questions
- What guidance did Abbott Laboratories give?
- On 2026-10-21: "FY2026 adjusted diluted EPS guidance $5.50-$5.55 (tightened from prior range); FY2026 comparable sales growth ~6.0%"
- When does Abbott Laboratories report earnings?
- Abbott Laboratories's next earnings report is expected on 2027-01-20.
Every figure on this page comes from Abbott Laboratories's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.